DexCom Analysts Increase Their Forecasts After Q4 Earnings

DexCom, Inc. DXCM reported weaker-than-expected earnings for its fourth quarter on Thursday.

The company posted quarterly earnings of 45 cents per share which missed the analyst consensus estimate of 50 cents per share. The company reported quarterly sales of $1.140 billion which beat the analyst consensus estimate of $1.104 billion.

“In 2024, we implemented our largest US commercial sales force expansion, had two major product launches with Dexcom One+ and Stelo and submitted our G7 15-day product to the FDA,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “As we enter 2025, we look forward to building on these investments as we unlock the next wave of access to Dexcom CGM globally.”

Dexcom reaffirmed its FY25 guidance for revenue of $4.60 billion (vs. cons. of $4.61 billion), adjusted gross profit margin of around 64%–65%, and adjusted operating margin of 21%. The company sees adjusted EBITDA margin of approximately 30%.

DexCom shares gained 0.3% to close at $84.09 on Thursday.

These analysts made changes to their price targets on DexCom following earnings announcement.

Morgan Stanley analyst Patrick Wood maintained DexCom with an Equal-Weight and raised the price target from $75 to $82.
Canaccord Genuity analyst William Plovanic maintained the stock with a Buy and raised the price target from $99 to $103.

Considering buying DXCM stock? Here’s what analysts think: